2024
Chapter 30 The emerging genetic landscape of renal cell carcinoma
Lee G, Shinder B, Sadimin E, Stephenson R, Singer E. Chapter 30 The emerging genetic landscape of renal cell carcinoma. 2024, 447-460. DOI: 10.1016/b978-0-12-822824-1.00035-3.ChaptersRenal cell carcinomaCell carcinomaOrgan-confined renal cell carcinomaKidney cancerMetastatic renal cell carcinomaLong-term survival outcomesLandscape of renal cell carcinomaDiagnosis of kidney cancerRenal tubule epithelial cellsTubule epithelial cellsGroup of diseasesSurgical resectionSystemic therapyDistant metastasisSurvival outcomesDiagnosed patientsEpithelial cellsPatientsPatient deathGenetic landscapeCarcinomaDiseaseCancerResectionMetastasis
2023
Predictive Biomarkers in Advanced Renal Cell Carcinoma
Shinder B, Kronstedt S, Hakimi A. Predictive Biomarkers in Advanced Renal Cell Carcinoma. 2023, 251-268. DOI: 10.1007/978-3-031-40901-1_11.ChaptersRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaPredictive biomarkersEra of treatment optionsCharacteristics of renal cell carcinomaPrediction of treatment responseOptimal therapeutic pathwayTargeted systemic therapyImmuno-oncology agentsRoutine clinical useSystemic therapyAdvanced diseaseClinical benefitTreatment responseTreatment optionsClinical useTherapeutic pathwaysCarcinomaPatientsBiomarkersMolecular characteristicsTherapyChromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation
Lichtbroun B, Shinder B, Sara T, Srivastava A, Saraiya B, Mayer T, Cristelli R, Sadimin E, Weiss R, Singer E. Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation. Journal Of Kidney Cancer And VHL 2023, 10: 1-8. PMID: 37441361, PMCID: PMC10334999, DOI: 10.15586/jkcvhl.v10i3.254.Peer-Reviewed Case Reports and Technical NotesChromophobe renal cell carcinomaSarcomatoid differentiationRenal cell carcinomaCell carcinomaClinical courseCases of ChRCCSystemic treatment optionsAggressive clinical courseMetastatic diseaseOverall survivalFavorable prognosisLarger tumorsClinicopathological dataPoor prognosisTreatment optionsPoor outcomeKidney cancerChRCCCarcinomaPrognosisDifferentiationSarcomatoidChromophobeTumorPatientsFactors associated with clinical trial participation for patients with renal cell carcinoma
Shinder B, Kim S, Srivastava A, Patel H, Jang T, Mayer T, Saraiya B, Ghodoussipour S, Singer E. Factors associated with clinical trial participation for patients with renal cell carcinoma. Urologic Oncology Seminars And Original Investigations 2023, 41: 208.e1-208.e8. PMID: 36868881, PMCID: PMC10106382, DOI: 10.1016/j.urolonc.2023.01.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaClinical trial participationClinical trialsOverall survivalClinical stageTrial patientsTrial participantsCharlson-Deyo comorbidity scoreAssociated with trial participationCompare overall survivalNational Cancer DatabaseLog-rank testClinical trial patientsPatient sociodemographic factorsAssociated with clinical trial participationMedian OSSuperior OSCancer DatabaseOncology clinical trialsSurvival outcomesMale patientsCase-control designPatient cohortControl cohort
2022
Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature
Cahill E, Tabakin A, Shinder B, Bramwit M, Saraiya B, Xu X, Salazar C, Zhou Z, Singer E. Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature. Journal Of Kidney Cancer And VHL 2022, 9: 32-38. PMID: 36118793, PMCID: PMC9431006, DOI: 10.15586/jkcvhl.v9i2.229.Peer-Reviewed Case Reports and Technical NotesRenal Cell Carcinoma with Testicular Metastases: A Case Report and Review of the Literature
Yoshitake S, Shinder B, Dazen K, Smith C, Mayer T, Sadimin E, Singer E. Renal Cell Carcinoma with Testicular Metastases: A Case Report and Review of the Literature. Journal Of Kidney Cancer And VHL 2022, 9: 22-26. PMID: 36118790, PMCID: PMC9430971, DOI: 10.15586/jkcvhl.v9i2.212.Peer-Reviewed Case Reports and Technical NotesFactors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma
Patel HV, Kim S, Srivastava A, Shinder BM, Sterling J, Saraiya B, Mayer TM, Ghodoussipour S, Jang TL, Singer EA. Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022, 20: 296-296.e9. PMID: 35105510, PMCID: PMC9149103, DOI: 10.1016/j.clgc.2022.01.001.Peer-Reviewed Original ResearchConceptsStage IV RCCMetastatic renal cell carcinomaNational Cancer DatabasePalliative interventionsRenal cell carcinomaMetastatic RCCClinical factorsCell carcinomaMultivariable logistic regression modelComprehensive cancer programsQuality of lifeLogistic regression modelsSarcomatoid histologyAdvanced malignanciesOverall cohortHigher education statusOncologic careInsurance statusCancer DatabaseCancer programsEarly initiationIntervention utilizationTreatment-specific mannerPatientsPI use
2021
EDITORIAL COMMENT.
Srivastava A, Shinder B, Singer EA. EDITORIAL COMMENT. Urology 2021, 158: 115. PMID: 34895625, DOI: 10.1016/j.urology.2021.04.076.Commentaries, Editorials and LettersFactors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct)
Patel H, Srivastava A, Shinder B, Kim I, Singer E, Ghodoussipour S, Jang T. Factors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct). Journal Of The American College Of Surgeons 2021, 233: e230. DOI: 10.1016/j.jamcollsurg.2021.08.622.Peer-Reviewed Original ResearchMP19-08 DISPARITIES IN CLINICAL TRIAL PARTICIPATION FOR PATIENTS WITH RENAL CELL CARCINOMA AND PROSTATE CANCER
Shinder B, Kim S, Patel H, Mayer T, Saraiya B, Jang T, Kim I, Singer E. MP19-08 DISPARITIES IN CLINICAL TRIAL PARTICIPATION FOR PATIENTS WITH RENAL CELL CARCINOMA AND PROSTATE CANCER. Journal Of Urology 2021, 206: e330-e330. DOI: 10.1097/ju.0000000000002004.08.Peer-Reviewed Original ResearchUrologic Issues in Palliative Care
3. Patel HV, Shinder BM, Metwalli AR, Pinto PA, Singer EA. Urologic Issues in Palliative Care. Principles and Practice of Palliative care and Support Oncology, 5e. Wolters Kluwer Health 2020. ISBN 978-1975143688Chapters
2020
Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond
Srivastava A, Patel HV, Kim S, Shinder B, Sterling J, Tabakin AL, Polotti CF, Saraiya B, Mayer T, Kim IY, Ghodoussipour S, Patel HD, Jang TL, Singer EA. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Urologic Oncology Seminars And Original Investigations 2020, 39: 247-257. PMID: 33223368, PMCID: PMC7574787, DOI: 10.1016/j.urolonc.2020.10.012.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaUpstaging riskOverall survivalCell carcinomaNonclear cell renal cell carcinomaOrgan-confined renal cell carcinomaCox proportional hazards modelNational Cancer DatabaseCell renal cell carcinomaKaplan-Meier curvesProportional hazards modelSmall renal massesCOVID-19Logistic regression modelsPT3a upstagingDelaying surgeryPrimary endpointSecondary endpointsPatient comorbiditiesMeier curvesElective surgeryRadical nephrectomyTumor histologyClinical stageRCC patientsThe human microbiome and genitourinary malignancies
Nicolaro M, Portal D, Shinder B, Patel H, Singer E. The human microbiome and genitourinary malignancies. Annals Of Translational Medicine 2020, 8: 1245. PMID: 33178777, PMCID: PMC7607065, DOI: 10.21037/atm-20-2976.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsImmune checkpoint inhibitorsTyrosine kinase inhibitorsGenitourinary malignanciesResponse to certain drugsCheckpoint inhibitorsPredictors of diseaseOncological outcomesEffects of antibioticsProstate cancerMicrobial signaturesUrological malignanciesEtiology of disease statesTreatment coursePrognostic indicatorBladder cancerSystemic inflammationHealthy patientsUrinary microbiomeKidney cancerKinase inhibitorsMalignancyGenitourinary diseasesHuman microbiomeTherapeutic targetCancerUrologic oncology surgery during COVID-19: a rapid review of current triage guidance documents
Shinder BM, Patel HV, Sterling J, Tabakin AL, Kim IY, Jang TL, Singer EA. Urologic oncology surgery during COVID-19: a rapid review of current triage guidance documents. Urologic Oncology Seminars And Original Investigations 2020, 38: 609-614. PMID: 32507546, PMCID: PMC7260595, DOI: 10.1016/j.urolonc.2020.05.017.Peer-Reviewed Original ResearchChallenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery.
Patel H, Shinder B, Srinivasan R, Singer E. Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. Current Opinion In Oncology 2020, 32: 240-249. PMID: 32195679, PMCID: PMC9788417, DOI: 10.1097/cco.0000000000000621.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellChemotherapy, AdjuvantClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCytoreduction Surgical ProceduresHumansKidney NeoplasmsNeoadjuvant TherapyNeoplasm MetastasisProtein Kinase InhibitorsRandomized Controlled Trials as TopicConceptsMetastatic renal cell carcinomaRenal cell carcinomaCell carcinomaBiology of metastatic renal cell carcinomaTreatment of metastatic renal cell carcinomaManagement of metastatic renal cell carcinomaTyrosine kinase inhibitor cabozantinibProgrammed cell death protein 1 antibodyIntroduction of novel therapiesCombination of axitinibFirst-line therapyUS Food and Drug AdministrationFood and Drug AdministrationCytoreductive surgeryAdvanced RCCSystemic therapyCombination therapySurvival benefitTargeted therapyPatient selectionTreatment paradigmNovel therapiesTherapeutic advancesCombinatorial therapyTreatment advances
2019
Primary Renal Ewing Sarcoma: A Case Report and Review of the Literature.
Findlay B, Shinder B, Fatima A, Sadimin E, Drachtman R, Parikh R, Singer E. Primary Renal Ewing Sarcoma: A Case Report and Review of the Literature. Journal Of Renal Cancer 2019, 2: 15-19. PMID: 32090210, PMCID: PMC7034944, DOI: 10.36959/896/603.Peer-Reviewed Case Reports and Technical NotesRetroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014
Tabakin AL, Shinder BM, Kim S, Rivera-Nunez Z, Polotti CF, Modi PK, Sterling JA, Farber NJ, Radadia KD, Parikh RR, Kim IY, Saraiya B, Mayer TM, Singer EA, Jang TL. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. Clinical Genitourinary Cancer 2019, 18: e194-e201. PMID: 31818649, DOI: 10.1016/j.clgc.2019.10.018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultFollow-Up StudiesHumansKaplan-Meier EstimateLymph Node ExcisionLymph NodesLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrchiectomyRegistriesRetroperitoneal SpaceRetrospective StudiesSeminomaSurvival RateTesticular NeoplasmsTestisTreatment OutcomeUnited StatesYoung AdultConceptsRetroperitoneal lymph node dissectionPrimary retroperitoneal lymph node dissectionLymph node dissectionOverall survivalTesticular seminomaNode dissectionRole of RPLNDTesticular nonseminomatous germ cell tumorsNational Cancer Data BaseNonseminomatous germ cell tumorsPrimary testicular cancerFive-year OSFirst-line treatmentKaplan-Meier methodOngoing prospective trialsGerm cell tumorsIIB diseaseOS ratesPrimary chemotherapyPrimary therapyProspective trialFinal cohortStage IIATumor histologyClinical stageMetastatic Prostate Cancer to the Renal Pelvis and Proximal Ureter: A Case Report and Review of the Literature.
Munshi F, Shinder B, Sadimin E, Mayer T, Singer E. Metastatic Prostate Cancer to the Renal Pelvis and Proximal Ureter: A Case Report and Review of the Literature. Cancer Studies And Therapeutics 2019, 4 PMID: 32148662, PMCID: PMC7059776.Peer-Reviewed Case Reports and Technical NotesRenal pelvisProstate cancerProximal ureterSymptoms of obstructive uropathyHigh index of suspicionFive-year survival rateMetastatic work-upMetastatic prostate cancerProstate cancer metastasisIndex of suspicionRight renal pelvisUreteral metastasisAsymptomatic massObstructive symptomsProstatic adenocarcinomaObstructive uropathyEventual metastasisLymph nodesCase reportClinical trial protocolsHigh indexVisceral diseaseWork-upSurvival rateProstateA Case Study Evaluating the Diagnosis and Treatment of a Rare Mesenchymal Tumor
Shinder B, Sack J, Sadimin E, Tunuguntla H. A Case Study Evaluating the Diagnosis and Treatment of a Rare Mesenchymal Tumor. Urology 2019, 131: e1-e2. PMID: 31247212, DOI: 10.1016/j.urology.2019.06.019.Peer-Reviewed Case Reports and Technical NotesConceptsCellular angiofibromaPainless right inguinal massRare mesenchymal tumorRight inguinal massBenign mesenchymal neoplasmLimited treatment optionsOval-shaped massSurgical excisionInguinal massMesenchymal tumorsMesenchymal neoplasmsCT scanTreatment optionsSpermatic cordImmunohistochemical analysisRadiographic featuresImaging modalitiesAngiofibromaDiagnostic casesCD34NeoplasmsTumorExcisionDesminCordSurvival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma.
Tabakin A, Kim S, Polotti C, Shinder B, Rivera-Nunez Z, Sterling J, Farber N, Radadia K, Kim I, Singer E, Jang T. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma. Journal Of Clinical Oncology 2019, 37: 534-534. DOI: 10.1200/jco.2019.37.7_suppl.534.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionOverall survival rateTesticular seminomaSurvival rateOverall survivalClinical stagePC settingsUnderwent retroperitoneal lymph node dissectionComprehensive community cancer programsFive-year overall survivalNational Cancer DatabaseCommunity cancer programsFirst-line treatmentLow-volume diseaseLymph node dissectionKaplan-Meier methodSurvival dataAvailable survival dataMajority of menNonseminoma histologyPrior chemotherapyNode dissectionSeminoma patientsFinal cohortOngoing trials